Sylvester Comprehensive Cancer Center

Stefan Gluck, M.D., Ph.D.

Stefan Gluck, M.D., Ph.D.

Professor of Medicine

Description of Research

Dr. Glück’s research interests include all aspects of clinical trials and translational research: Phase I, II and III studies, impact of participation in clinical trials, ethnic diversity in outcome, participation, side effects and behavioral projects. In collaboration with basic scientists, his expertise is to identify druggable targets and bring those into early clinical research. Within his team he was able to show differences in a variety of ethnic groups as we see them in Miami area of tumor composition including immunocompetent cellularity. Particular focus is investigating a specific, aggressive group of breast cancers, “triple negative breast cancer” with its at least 7 different subsets. A number of clinical trials and research projects are underway. Two of such rivals are in collaboration with Nobel Price Laureates, and additional studies with industry. This is particularly exciting, since in the past, no promising approaches other than chemotherapy were available for patients with such triple negative tumors.


  • Most recently, Dr. Gluck and his team were able to show that molecular profiling in breast cancer leads to more precise prognosis of long term outcomes and also has predictive power to utilize specific drugs and compounds in early breast cancer tailored to the needs of individual patients; This approach is now recognized as “precision” or “personalized medicine”.

Selected Cancer-Related Publications

  • Byrne MM, Tannenbaum SL, Glück S, Hurley J, Antoni M. Participation in cancer clinical trials: why are patients not participating? Med Decis Making 34:116-26,2014 Read more »
  • Carrio R, Koru-Sengul T, Miao F, Glück S, Lopez O, Selman Y, Alvarez C, Milikowski C, Gomez C, Jorda M, Nadji M, Torroella-Kouri M. Macrophages as independent prognostic factors in small T1 breast cancers. Oncol Rep 29:141-8,2013 Read more »
  • Chow LW, Tung SY, Ng TY, Im SA, Lee MH, Yip AY, Toi M, Glück S. Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study. Expert Opin Investig Drugs 22:299-307,2013 Read more »
  • Arango BA, Rivera CL, Glück S. Gene expression profiling in breast cancer. Am J Transl Res 5:132-8,2013 Read more »
  • Bayraktar S, Glück S. Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat 138:21-35,2013 Read more »
  • Glück S, de Snoo F, Peeters J, Stork-Sloots L, Somlo G. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Res Treat 139:759-67,2013 Read more »
  • Glück S, von Minckwitz G, Untch M. Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer. Breast 22:142-9,2013 Read more »
  • Glück S. Extending the Clinical Benefit of Endocrine Therapy for Women With Hormone Receptor-Positive Metastatic Breast Cancer: Differentiating Mechanisms of Action. Clin Breast Cancer :,2013 Read more »
  • Kittaneh M, Montero AJ, Glück S. Molecular Profiling for Breast Cancer: A Comprehensive Review. Biomark Cancer 5:61-70,2013 Read more »
  • Lopes G, Glück S, Avancha K, Montero AJ. A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer. Breast Cancer Res Treat 137:187-93,2013 Read more »
  • Tinoco G, Warsch S, Glück S, Avancha K, Montero AJ. Treating breast cancer in the 21st century: emerging biological therapies. J Cancer 4:117-32,2013 Read more »
  • Vargas S, Antoni MH, Carver CS, Lechner SC, Wohlgemuth W, Llabre M, Blomberg BB, Glück S, Derhagopian RP. Sleep Quality and Fatigue after a Stress Management Intervention for Women with Early-Stage Breast Cancer in Southern Florida. Int J Behav Med :,2013 Read more »
  • Westin GF, Perez CA, Wang E, Glück S. Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer. Int J Biol Markers 28:233-241,2013 Read more »
  • Cortes J, Montero AJ, Glück S. Eribulin mesylate,a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treat Rev 38:143-51,2012 Read more »
  • Montero A, Glück S. Long-Term Complete Remission with nab-Paclitaxel,Bevacizumab,and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer. Case Rep Oncol 5:687-92,2012 Read more »
  • Montero AJ, Avancha K, Glück S, Lopes G. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res Treat 132:747-51,2012 Read more »
  • Montero AJ, Diaz-Montero CM, Deutsch YE, Hurley J, Koniaris LG, Rumboldt T, Yasir S, Jorda M, Garret-Mayer E, Avisar E, Slingerland J, Silva O, Welsh C, Schuhwerk K, Seo P, Pegram MD, Glück S. Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Res Treat 132:215-23,2012 Read more »
  • Montero AJ, Escobar M, Lopes G, Glück S, Vogel C. Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr Oncol Rep 14:1-11,2012 Read more »
  • Ochoa R, Bejarano PA, Glück S, Montero AJ. Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review. J Med Case Rep 6:413,2012 Read more »
  • Glück S, Yip AY, Ng EL. Can we replace the microscope with microarrays for diagnosis,prognosis and treatment of early breast cancer? Expert Opin Ther Targets 16 Suppl 1:S17-22,2012 Read more »
  • Ahn ER, Wang E, Glück S. Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence,Recommendations,and Ethical Issues Regarding Dual HER2-Targeted Therapy. Breast Cancer (Auckl) 6:191-207,2012 Read more »
  • Glück S, Ross JS, Royce M, McKenna EF Jr, Perou CM, Avisar E, Wu L. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treat 132:781-91,2012 Read more »
  • Bayraktar S, Glück S. Systemic therapy options in BRCA mutation-associated breast cancer. Breast Cancer Res Treat 135:355-66,2012 Read more »
  • Blum JL, Kohles J, McKenna E, Scotto N, Hu S, Odom D, Kaye JA, Glück S. Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. Breast Cancer Res Treat 125:431-439,2011 Read more »
  • Glück S, Arteaga CL, Osborne CK. Optimizing Chemotherapy-Free Survival for the ER/HER2-Positive Metastatic Breast Cancer Patient. Clin Cancer Res 17:5559-61,2011 [JIF 7.338] Read more »
  • Glück S, Gorouhi F. Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer. Am J Health Syst Pharm 68:1699-706,2011 Read more »
  • Han HS, Reis IM, Zhao W, Kuroi K, Toi M, Suzuki E, Syme R, Chow L, Yip AY, Glück S. Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer 47:2537-45,2011 Read more »
  • Kittaneh M, Glück S. Exemestane in the adjuvant treatment of breast cancer in postmenopausal women. Breast Cancer (Auckl) 5:209-26,2011 Read more »
  • Montero AJ, Adams B, Diaz-Montero CM, Glück S. Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Expert Rev Clin Pharmacol 4:329-34,2011 Read more »
  • Bayraktar S, Garcia-Buitrago MT, Hurley E, Gluck S. Surviving metastatic breast cancer for 18?years: a case report and review of the literature. Breast J 17:521-4,2011 Read more »
  • Montero AJ, Talebi TN, Zhu Y, Branch KD, Goldsberry GT, Baker MK, Gluck S. Successful Use of Biweekly Gemcitabine Plus Nab-Paclitaxel in Two Male Patients With Stage IV Breast Cancer: Case Reports and Review of the Literature. Am J Ther 18:e12-8,2011 Read more »


Collaborating in the Multidisciplinary Research Program(s):

E-mail a Friend